

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

HAN SUNG INTERNATIONAL PATENT &
LAW OFFICE
4th floor
Halla Classic Bldg.
824-11, Yoksam-Dong
Kangnam-ku
Seoul 135-080
RÉPUBLIQUE DE CORÉE

Date of mailing (day/month/year)
15 February 2002 (15.02.02)

Applicant's or agent's file reference
PCT-99081

International application No.
PCT/KR99/00460

IMPORTANT NOTIFICATION

International filing date (day/month/year)
18 August 1999 (18.08.99)

1. The following indications appeared on record concerning:

☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address

KIM, Ho-Youn
PARK, Jong-Sang
applicant/inventors for all designated States

State of Nationality

KR

State of Residence

KR

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

CATHOLIC EDUCATIONAL FOUNDATION
#505, Banpo-Dong
Seocho-ku
Seoul
Republic of Korea
Applicant for all designated States except US

State of Nationality

KR

State of Residence

KR

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

The applicant/inventors in box (1) have assigned their rights to the applicant in box (2)
and are now recorded as applicant/inventors for the US only.

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned
☐ the International Searching Authority ☒ the elected Offices concerned
☐ the International Preliminary Examining Authority ☐ other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Anne BEUCHAT

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

HAN SUNG INTERNATIONAL PATENT &
LAW OFFICE
4th floor
Halla Classic Bldg.
824-11, Yoeksam-Dong
Kangnam-ku
Seoul 135-080
RÉPUBLIQUE DE CORÉE

Date of mailing (day/month/year) 04 February 2002 (04.02.02)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference PCT-99081	
International application No. PCT/KR99/00460	International filing date (day/month/year) 18 August 1999 (18.08.99)

1. The following indications appeared on record concerning: <input type="checkbox"/> the applicant <input type="checkbox"/> the inventor <input checked="" type="checkbox"/> the agent <input type="checkbox"/> the common representative		
Name and Address YOON, Dong-Yol 8th floor Dae-Heung Building 648-23, Yoksam-dong Kangnam-ku Seoul 135-748 Republic of Korea	State of Nationality	State of Residence
	Telephone No. 8225671107	
	Facsimile No. 8225581150	
	Teleprinter No.	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning: <input checked="" type="checkbox"/> the person <input type="checkbox"/> the name <input type="checkbox"/> the address <input type="checkbox"/> the nationality <input type="checkbox"/> the residence		
Name and Address HAN SUNG INTERNATIONAL PATENT & LAW OFFICE 4th floor Halla Classic Bldg. 824-11, Yoeksam-Dong Kangnam-ku Seoul 135-080 Republic of Korea	State of Nationality	State of Residence
	Telephone No. 8225556888	
	Facsimile No. 8225559888	
	Teleprinter No.	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to: <input checked="" type="checkbox"/> the receiving Office <input type="checkbox"/> the designated Offices concerned <input type="checkbox"/> the International Searching Authority <input checked="" type="checkbox"/> the elected Offices concerned <input type="checkbox"/> the International Preliminary Examining Authority <input type="checkbox"/> other:		

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Ning XU Telephone No.: (41-22) 338.83.38
---	---

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE
in its capacity as elected Office

Date of mailing (day/month/year) 25 April 2001 (25.04.01)	
International application No. PCT/KR99/00460	Applicant's or agent's file reference PCT-99081
International filing date (day/month/year) 18 August 1999 (18.08.99)	Priority date (day/month/year)
Applicant KIM, Ho-Youn et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
28 February 2001 (28.02.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p style="text-align: center;">The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer</p> <p style="text-align: center;">S. Mafla</p> <p>Telephone No.: (41-22) 338.83.38</p>
---	---

PATENT COOPERATION TREATY

PCT

NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

From the INTERNATIONAL BUREAU

To:

YOON, Dong-Yol
8th floor
Dae-Heung Building
648-23, Yoksam-dong
Kangnam-ku
Seoul 135-748
RÉPUBLIQUE DE CORÉE



Date of mailing (day/month/year) 22 February 2001 (22.02.01)		
Applicant's or agent's file reference PCT-99081		IMPORTANT NOTICE
International application No. PCT/KR99/00460	International filing date (day/month/year) 18 August 1999 (18.08.99)	
Priority date (day/month/year)		
Applicant KIM, Ho-Youn et al		

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:
AU,KP,KR,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:

**AE,AL,AM,AP,AT,AZ,BA,BB,BG,BR,BY,CA,CH,CN,CU,CZ,DE,DK,EA,EE,EP,ES,FI,GB,GD,GE,GH,
GM,HR,HU,ID,IL,IN,IS,JP,KE,KG,KZ,LC,LK,LR,LS,LT,LU,LV,MD,MG,MK,MN,MW,MX,NO,NZ,OA,
PL,PT,RO,RU,SD,SE,SG,SI,SK,SL,TJ,TM,TR,TT,UA,UG,UZ,VN,YU,ZA,ZW**

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on
22 February 2001 (22.02.01) under No. WO 01/12222

REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer J. Zahra
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

REC'D 07 DEC 2001

INTERNATIONAL PRELIMINARY EXAMINATION REPORT PCT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PCT-99081		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/KR 99/00460	International filing date (<i>day/month/year</i>) 18 August 1999 (18.08.1999)	Priority Date (<i>day/month/year</i>)	
International Patent Classification (IPC) or national classification and IPC IPC ⁷ : A61K 39/39, 38/02; C07K 14/435, 14/78, 17/08			
Applicant KIM, Ho-Youn et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examination Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>4</u> sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of <u>3</u> sheets.</p> <p>3. This report contains indications relating to the following items:</p> <p>I. <input checked="" type="checkbox"/> Basis of the opinion</p> <p>II. <input type="checkbox"/> Priority</p> <p>III. <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV. <input type="checkbox"/> Lack of unity of invention</p> <p>V. <input checked="" type="checkbox"/> Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI. <input type="checkbox"/> Certain documents cited</p> <p>VII. <input type="checkbox"/> Certain defects in the international application</p> <p>VIII. <input type="checkbox"/> Certain observations on the international application</p>			
Date of submission of the demand 28 February 2001 (28.02.2001)		Date of completion of this report 13 November 2001 (13.11.2001)	
Name and mailing address of the IPEA/AT Austrian Patent Office Kohlmarkt 8-10 A-1014 Vienna Facsimile No. 1/53424/200		Authorized officer KRENN Telephone No. 1/53424/435	

Form PCT/IPEA/409 (cover sheet) (July 1998)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/KR 99/00460

I. Basis of the report

1. With regard to the elements of the international application:*

☐ the international application as originally filed

☒ the description:

pages 1-28,32, as originally filed

pages _____, filed with the demand

pages _____, filed with the letter of _____.

☒ the claims:

pages _____, as originally filed

pages _____, as amended (together with any statement) under Article 19

pages _____, filed with the demand

pages 29-31, filed with the letter of 6 July 2001 (06.07.2001).

☒ the drawings:

pages 1-12, as originally filed

pages _____, filed with the demand

pages _____, filed with the letter of _____.

☐ the sequence listing part of the description:

pages _____, as originally filed

pages _____, filed with the demand

pages _____, filed with the letter of _____.

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

☐ the language of publication of the international application (under Rule 48.3(b)).

☐ the language of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☐ contained in the international application in printed form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages _____.

☐ the claims, Nos. _____.

☐ the drawings, sheets/fig _____.

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as „originally filed“ and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application,
☒ claims Nos. 1-15 (please see remark)

because:

- ☒ the said international application, or the said claims Nos. 1-15
relate to the following subject matter which does not require an international preliminary examination (*specify*):

Remark:

Although claims 1-15 are directed to a therapeutic methods of treatment of the human/animal body, the examination has been carried out and is based on the alleged effects of the composition (see PCT-Rule 39.1 iv).

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _____
are so unclear that no meaningful opinion could be formed (*specify*):

- ☐ the claims, or said claims Nos. _____ are so inadequately supported
by the description that no meaningful opinion could be formed.

- ☐ no international search report has been established for said claims Nos. _____

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
☐ the computer readable form has not been furnished or does not comply with the standard.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/KR 99/00460V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
citations and explanations supporting such statement

I. Statement			
Novelty (N)	Claims	1-17	YES
	Claims		NO
Inventive step (IS)	Claims	1-17	YES
	Claims		NO
Industrial applicability (IA)	Claims	16,17	YES
	Claims	1-15	NO

Citations and explanations (Rule 70.7)

After amendment of claims 1,8,16 and 17 both novelty and inventive step are still given for the whole application.

Since the subject matters of claims 1-15 refer to therapeutic methods of treatment of the human/animal body, industrial applicability is still given only for claims 16 and 17.

REPLACED BY
ART 34 AMDT

CLAIMS

1. A method for treating autoimmune diseases, which comprises administering orally to a mammal suffering from autoimmune diseases particles of biodegradable polymers in an amount of effective to induce tolerance against autoimmune response.
- 5 2. The method according to Claim 1, wherein said biodegradable polymers are poly(DL-lactide-co-glycolide), polylactides or polyglycolides.
3. The method according to Claim 1, wherein said autoimmune diseases are one of Th1-mediated or T cell-mediated autoimmune diseases selected from the group consisting of rheumatoid arthritis, insulin dependnent diabetes mellitus,
10 uveitis, multiple sclerosis, autoimmune thyroiditis, autoimmune hepatitis, interstitial pneumonitis and glomerulonephritis, and their corresponding diseases in animal models.
4. The method according to Claim 3, wherein said autoimmune disease is rheumatoid arthritis.
- 15 5. The method according to any one of Claim 1 to Claim 4, wherein said mammal is human, rats, mice and monkeys.
6. The method according to any one of Claim 1 to Claim 4, wherein a single dose of said particles is administered to induce tolerance against autoimmune response.
- 20 7. The method according to any one of Claim 1 to Claim 4, wherein said particles have a size of less than about 500nm.

8. A method for treating autoimmune diseases, which comprises administering orally to a mammal suffering from autoimmune diseases particles of biodegradable polymers entrapping an autoimmune antigen, said particles being administered in an amount of effective to induce tolerance against autoimmune
5 response.

9. The method according to Claim 8, wherein said biodegradable polymers are poly(DL-lactide-co-glycolide), polylactides or polyglycolides.

10. The method according to Claim 8, wherein said autoimmune diseases are one of selected from the group consisting of rheumatoid arthritis, collagent induced
10 arthritis, multiple sclerosis, experimental autoimmune encephalomyelitis, insulin-dependent diabetes mellitus, experimental diabete mellitus and uveitis.

11. The method according to Claim 10, wherein said autoimmune disease is rheumatoid arthritis.

12. The method according to Claim 8, wherein said antigen is type II collagen,
15 S antigen, major basic protein, glutamic acid decarboxylase, or immunodominant peptide fragments thereof.

13. The method according to any one of Claim 8 to Claim 12, wherein said mammal is human, rats, mice and monkeys.

14. The method according to any one of Claim 8 to Claim 12, wherein a single
20 dose of said particles is administered to induce tolerance against autoimmune response.

15. The method according to any one of Claim 8 to Claim 12, wherein said particles have a size of less than about 500nm.

16. A composition for inducing tolerance for autoimmune diseases, which comprises as an active ingredient particles of biodegradable polymers in an amount
5 of effective to induce tolerance against autoimmune response.

17 A composition for inducing tolerance for autoimmune diseases, which comprises as an active ingredient particles of biodegradable polymers entrapping an autoimmune antigen in an amount of effective to induce tolerance against autoimmune response.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12222 A1

(51) International Patent Classification⁷: **A61K 39/39**,
38/02, C07K 14/435, 14/78, 17/08

Seoul 137-780 (KR). **KIM, Wan-Uk** [KR/KR]; No.
503-901, Mido 2nd Apartment, Banpo-dong, Seocho-ku,
Seoul 137-769 (KR).

(21) International Application Number: PCT/KR99/00460

(22) International Filing Date: 18 August 1999 (18.08.1999)

(74) Agents: **YOON, Dong-Yol** et al.; 8th floor, Dae-Heung
Building, 648-23, Yoksam-dong, Kangnam-ku, Seoul
135-748 (KR).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ,
VN, YU, ZA, ZW.

(71) Applicants and

(72) Inventors: **KIM, Ho-Youn** [KR/KR]; 5-205, Daelim
Apartment, Ohkum-dong, Songpa-ku, Seoul 138-737
(KR). **PARK, Jong-Sang** [KR/KR]; 18-1001, Eunma
Apartment, Daechi-dong, Kangnam-ku, Seoul 135-778
(KR).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,
BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **RYOO, Zae-Young**
[KR/KR]; 211-606, Jugong Apartment, Sanbon-dong,
Gunpo-City, Kyunggi-do 435-040 (KR). **BAE, Euiy-
oung** [KR/KR]; 301, Hanmi Villa, 54-4, Banpo-dong,
Seocho-ku, Seoul 137-040 (KR). **LEE, Woo-Kyoung**
[KR/KR]; 1572-16, Shillim-11-dong, Kwanak-ku, Seoul
151-021 (KR). **CHO, Chul-Soo** [KR/KR]; No. B-503,
Samho Garden Apartment, 32-8, Banpo-dong, Seocho-ku,
Seoul 137-761 (KR). **PARK, Sung-Hwan** [KR/KR]; No.
104-1804, Youwon Apartment, Seocho-dong, Seocho-ku,


Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: IMMUNOLOGICAL TOLERANCE-INDUCTION AGENT

(57) Abstract: A method for treating
autoimmune diseases by administering
orally to a mammal suffering from
autoimmune diseases particles of
biodegradable polymers or their complex
with an autoimmune antigen is provided.
Only single administration can effectively
induce oral tolerance to autoimmune
diseases, resulting in a strong and
prolonged suppress of the diseases.



WO 01/12222 A1

IMMUNOLOGICAL TOLERANCE-INDUCTION AGENT

FIELD OF THE INVENTION

1. FIELD OF THE INVENTION

The present invention relates to an immunological tolerance-induction agent.
5 More particularly, it relates to a use of biodegradable polymers as an immunological tolerance-induction agent and a method for treating autoimmune diseases in mammals.

2. DESCRIPTION OF THE PRIOR ARTS

Injection of a foreign substance (referred to as 'antigen') into a vertebrate
10 organism may result in the induction of an immune response characterized by the production of specific antibodies capable of interacting with the antigen or the development of effector T lymphocytes and the precaution of soluble mediators at the site of encounter with the antigen. Although antibodies and T lymphocytes do play an essential role in protecting against hostile antigen, they can also participate in
15 injurious processes, leading to destruction of host tissues. This is the case in autoimmune diseases where one's own antibodies and/or T lymphocytes react with antigen of one's own tissues and damage the tissues. This also is the case in allergic reactions characterized by an exaggerated immune response to certain environmental matters and which may result in inflammatory responses leading to tissue destruction.

20 An approach to treat effectively the diseases caused by unwanted or tissue damaging immunological reactions such as autoimmune diseases is to specifically suppress or decrease to an acceptable level the intensity of deleterious immune

processes without affecting the remainder of the immune system. Immunological tolerance deals with all mechanisms that ensure an absence of destructive immune response to any given foreign substance.

Orally administered autoantigens suppress autoimmunity in animal models, including experimental allergic encephalomyelitis (EAE), collagen-induced arthritis (CIA), uveitis, and diabetes in the non-obese diabetic mouse (1-4). Oral tolerance describes the observation that a state of hyporesponsiveness follows an immunization with a previously and repetitively fed protein. Recently, the antigen-specific tolerance induction has been utilized as a treatment for various autoimmune diseases. For example, the repetitive administration of type II collagen (CII) or major basic protein (MBP; myeline basic protein) has been reported to be effective for the treatment of CIA or EAE, respectively. Likewise, oral administration of S-antigen can suppress the development of experimental uveitis (1-4). Oral tolerance induction has advantages that it doesn't elicit side effects including leukopenia, increased susceptibility of infection or malignance which can be induced by other drugs used currently for treating autoimmune disease, since it can selectively inhibit pathologic immune responses rather than non-specific immune suppression. However, irrespective of apparent ideality of oral tolerance induction, only few reports described the effectiveness of the oral tolerance in human disease, and even the results are not entirely uniform.

Several factors may affect the effectiveness of tolerance induction. Nature of antigen (soluble or particulate antigens) (5), antigen dose (6,7), genetic background (8), role of digestive flora (9), and antigen uptake (10) are known to be important factors in the determination of tolerance effect. In particular, oral tolerance is associated with the presence of immunologically relevant antigen in circulation. The amount of antigen absorbed intactly varies widely and is extremely small, ranging from 0.001% to 1% of the administered dose, which is partly attributed to the intraluminal digestion before the absorption of antigen (10-12). In this respect, the

enhancement of the absorption rate of antigen administered orally seem to be promising in the tolerance therapy of human autoimmune disease.

Biodegradable microparticles have been studied as a drug carrier system, because of their advantages such as enhanced absorption, biocompatibility, sustained
5 drug release and so on (13-15). Particularly, since particles can slowly release any entrapping substances into surroundings for a long period, they can deliver several kinds of drugs, hormones, and vaccines for 1 to 3 months, even though they are administered only once. Recently, it has been reported that particulate antigens administered orally are absorbed well into Peyer's patches, which are the primary
10 immune system of the gastrointestinal tract (16-18). Furthermore, soluble antigens entrapped by particulates can be protected from acidic and enzymatically hostile environments found at mucosal surfaces, facilitating uptake of the antigens by M cells overlying Peyer's patches and mucosal epithelium, thereby promoting antigen transport to local lymphoid follicles and associated lymph node, and possibly
15 enabling the local accumulation of the antigen (19-22). Owing to these properties of particulate antigens, studies for particles are mainly focused on the vaccine delivery system in immunology.

Possible accumulation of particulate antigens in Peyer's patch and subsequent translocation to discrete anatomical compartments such as liver and spleen could
20 modulate both mucosal and systemic immune responses. Recently, it is documented that several kinds of polymer have a potential to suppress pathologic immune response. Copolymer 1, a synthetic amino acid copolymer composed of L-alanine, L-glutamic acid, L-lysine, and L-tyrosine, has a beneficial effect on the development of EAE that is associated with down-regulation of T cell immune responses to MBP,
25 an autoantigen of EAE, and is mediated by Th2/3 type regulatory cells (23). In CIA, copolymer 1 also competitively inhibits the interaction of CII with RA-associated HLA-DR molecules and thereby suppresses CII reactive T cell responses (24). Polyethylene glycol (PEG), another straight amphophilic polymer, is also proved to

prevent arthritis in CIA (25). To the contrary, it is reported that silicone polymer-grafted starch microparticles facilitate mucosal antigenicity although they does not retard the release of antigen or protect antigen from degradation, suggesting their advantageous use for oral vaccine delivery (26). Sum of the previous findings
5 suggests that immunogenicity to particulate antigens administered orally may be different depending on the types and sizes of particles, *in vivo*. Moreover, the fate and role of particulate antigens in tolerance induction, if any, remain to be defined *in vivo*.

Rheumatoid arthritis (RA) is a representative autoimmune disease in human and characterized by destructive polyarthritis. Although the etiologic agent of RA
10 remains unclear, CII is a strong candidate because of its abundance in cartilage, an immunologically privileged tissue, and because of its ability to induce destructive immune-mediate polyarthritis after immunization of susceptible rodents and higher primates (27,28). Lymphocytes responding to CII are identified in the peripheral blood, or in the joints of patients with RA (29), and antibodies to CII are also evident
15 in the sera, synovial fluid (SF), and cartilage in patients with RA (30,31), suggesting CII may act as an autoantigen in human RA.

Antigen-specific immune suppression using CII has been tested in human RA. Even though orally administered CII shows an active suppression of arthritis in the animal model of RA, the oral tolerance using CII in human RA is not consistent
20 between the experiments. Barnett *et al* have demonstrated that oral CII therapy is effective in most RA patients (32). In contrast, Sieper *et al* have reported that only a minority of patients responded to treatment with oral CII (33). Thus, it is unclear whether oral tolerance induction using CII could be an effective strategy in the treatment of human RA.

25 Controversial effect of oral tolerance therapy in human disease is also noted in other autoimmune diseases. This may be attributed to the insufficient antigen delivery into Peyer's patches in the intestine, main machinery of oral tolerance induction. Unfortunately, only very few attempts to overcome the intraluminal

digestion and to enhance the rate and amount of antigen have been made in tolerance induction. Although the particles composed of polymer and protein have been proved for their usefulness for protein delivery, there has been no attempt to test or suggestion of the ability of PLGA particles or of active ingredients-entrapping PLGA particles to induce tolerance has been made.

Additional variable to determine the usefulness of tolerance therapy is easy availability of autoantigens including CII, MBP, S-antigens, and glutamic acid decarboxylase (GAD). Since these antigens should be purified from live animals to administer into human, they are expensive and have a risk of transferring some viruses contained in animals to human. In this respect, practical usefulness of these antigens is limited in treating human disease. Recently, it has been reported that the synthetic peptides encompassing immunodominant portions of afore-mentioned autoantigens, also can suppress the development of autoimmune disease, just like a whole molecule of antigen (34, 35, 36, 37 and 38).

Synthetic peptides may be utilized to treat autoimmune diseases such as RA, multiple sclerosis, and uveitis, without the drawbacks associated with the difficulty in purifying autoantigens from animals. Tolerance induction using synthetic immunodominant peptides seems to be promising since these peptides may be prepared in an easy and economic way as well as they have no risk to transfer viral diseases.

The inventors conducted a series of oral tolerance induction using biodegradable polymer particles with or without an autoimmune antigen or its immunodominant peptide fragments entrapped therein in an animal experimental model of RA, a representative autoimmune disease, and tested the ability of polymer particles to induce tolerance and mechanisms thereof by immunologic assays and electron microscopy, and as result thereof, found out that the polymer particles can induce oral tolerance against autoimmune diseases and enhance oral tolerance of autoimmune antigens.

SUMMARY OF THE INVENTION

The present invention provides a method for treating autoimmune diseases, which comprises administering orally to a mammal suffering from autoimmune diseases particles of biodegradable polymers, in particular poly(DL-lactide-co-glycolide) in an amount of effective to induce tolerance against autoimmune response.

The present invention further provides a method for treating autoimmune diseases, which comprises administering orally to a mammal suffering from autoimmune diseases particles of biodegradable polymers entrapping an autoimmune antigen, said particles being administered in an amount of effective to induce tolerance against autoimmune response.

The present invention still provides a use of biodegradable polymers as an inducer or enhancer for oral tolerance against autoimmune diseases.

The above and other objects, features and applications of the present invention will be apparent to those of ordinary skill by the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a SEM(Scanning Electron Microscopy) analysis depicting the PLGA particles entrapping type II collagen(PLGA-CII), in which the arrows indicate the diameter of a particle, approximating 300nm;

Figure 2 is *in vitro* release of CII from PLGA particles, showing a slow release profile over 4 weeks and typical biphasic pattern;

Figure 3(a) and 3(b) are graphs depicting the severity and incidence of arthritis with the lapse of time in a mice having a collagen-induced arthritis, respectively;

Figure 4 is a clinical assessment of arthritis in mice fed with PLGA-CII, native

CII or acetic acid following subsequent challenges with CII and CFA. Data were expressed by mean arthritis index(Figure 4(a)), incidence of arthritic mice(Figure 4(b)), and percent arthritic limb(Figure 4(c)). In Figure 4(b) and 4(c), -●- denotes mice fed with PLGA-CII (40 μ g, once), -■- mice fed with CII (5 μ g, eight times), and
5 -▲- mice fed with acetic acid (control). P value: * < 0.05, ** < 0.01, and *** < 0.001;

Figure 5 shows paw swelling of arthritic limbs in mice fed with CII or PLGA-CII (left) and those fed with acetic acid (right);

Figure 6(a) and 6(b) show tolerogenic effect of PLGA entrapping an immunodominant peptide fragment of CII ('CII(255-274)');

10 Figure 7 shows tolerogenic effect of PLGA itself in term of clinical symptoms. Data were expressed by mean arthritis index(Figure 7(a)), incidence of arthritic mice(Figure 7(b) left), and percent arthritic limb(Figure 7(b) right).

Figure 8(a) shows the immunosuppressive effect of PLGA-CII or CII on IgG antibodies to CII and 8(b) shows the effect of PLGA-CII on T cell proliferative
15 responses to CII;

Figure 9(a) and 9(b) are electron microscopic photographs for identifying PLGA particles in Peyer's patches, in which dendritic cell on day 14 and 35 after first feeding in Peyer's patch of mouse fed CII (5 μ g, eight times)(a) and dendritic cell in Peyer's patch of mouse fed PLGA-CII (40 μ g, once) on day 14 and 35 after feeding
20 (b). In Figure 9, black arrows denote an intact form of PLGA particles, approximating 300nm in size, in the cytoplasm, and white arrow denotes a degraded form of PLGA particles in the lysozyme granule of dendritic cells; and

Figure 10 is a CII-specific immunohistochemical staining of Peyer's patches. Arrow indicates CII stained.

The present invention provides a use of biodegradable polymer particles, in particular polylactide-polyglycolide (PLGA) particles as an inducer of oral immunological tolerance, especially for autoimmune diseases.

The biodegradable polymers may contain an autoimmune antigen entrapped
5 therein to enhance oral tolerance in mammals.

The term of 'autoimmune antigen' used herein means tissue-specific antigens that are themselves the subject of autoimmune attack and may include, among others, antigens of EAE, CIA, uveitis, multiple sclerosis, insulin dependent diabetes mellitus (IDDM) and the like. In specifically, it include type II collagen, major basic protein
10 (MBP), glutamic acid decarboxylase (GAD), S antigen and the like as well as immunodominant peptide fragments thereof. The immunodominant peptide fragments are known to those skilled in the art and may include the following SEQ. ID. NO. 1 through SEQ. ID. NO. 11 as well as their equivalents as long as they retain immunogenic property :

15 1) Rheumatoid arthritis (35)

CII (74-93); ARGFPGLPGLPGGVKGHRGYP (SEQ. ID. NO. 1)

CII (254-273); TGGKPGIAGFKGEQGPKGEP (SEQ. ID. NO. 2)

CII (924-943); PGERGLKGHRGFTGLQGLPG (SEQ. ID. NO. 3)

CII (255-270); CGEBGIAGFKGEQGPK (SEQ. ID. NO. 4)

20 2) Multiple sclerosis (36,37)

Myelin proteolipid protein (PLP) (139-151); HSLGKWLGHDPKF
(SEQ. ID. NO. 5)

PLP (178-191); NTWTTCQSIAFPSK (SEQ. ID. NO. 6)

PLP (258-273); IAATYNFAVLKLMGRG (SEQ. ID. NO. 7)

25 Major basic protein (87-99); VHFFKNIVTPRTP (SEQ. ID. NO. 8)

Myelin oligodendrocyte glycoprotein (92-106); DEGGYTCFFRDHSYQ
(SEQ. ID. NO. 9)

3) Autoimmune Uveitis (38)

S antigen (343-362); LGELTSSEVATEVPFRLMHP (SEQ. ID. NO. 10)

4) IDDM (42)

Glutamic acid decarboxylase-65 (524-543); SRLSKVAPVIKARMMEYGT

5 (SEQ. ID. NO. 11)

The sequence of the immunodominant peptide fragments may be slightly varied depending on their origins, and the present invention encompasses the polymer particles entrapping the peptide fragments regardless of their origin as long as they show the tolerance inducing property in living body. Both of synthetic and naturally occurring peptide fragments may be employed according to the present invention, and synthetic peptide fragments are advantageously used due to easy and unexpensive production thereof.

The term of 'autoimmune disease' used herein means a condition where the immune system mistakenly perceives the body's own tissue as foreign and mounts an abnormal immune response against it and may include experimental allergic encephalomyelitis (EAE), collagen induced arthritis (CIA), rheumatoid arthritis (RA), uveitis, multiple sclerosis, IDDM, non-obese diabetes, and the like. Rheumatoid arthritis can be advantageously treated by the present invention. In particular, the polymer particles without antigen can advantageously be used to treat Th1-mediated or T cell-mediated autoimmune diseases such as rheumatoid arthritis, IDDM, uveitis, multiple sclerosis, autoimmune thyroiditis (e.g., Grave's disease, Hashimoto's thyroiditis), autoimmune hepatitis, interstitial pneumonitis or glomerulonephritis, and their corresponding diseases in animal models.

Throughout the application, the term of 'polymers' or 'PLGA', or the part of 'PLGA' in the terms of 'PLGA-CII' (or 'PLGA entrapping CII'), or 'PLGA-CII(amino acid number)' should be understood to indicate particles made therefrom having the desired size unless they are intentionally used to stand for the compound


itself. Moreover, the term of 'particle(s)' is used to indicated to include both the polymer particles and the antigen-entrapping polymer particles, unless indicated otherwise.

The autoimmune antigen which will be entrapped by biodegradable polymers
5 may be selected by those skilled in the art without difficulty depending on the kind of the autoimmune diseases to be treated. For example, CII or its immunodominant peptides will be entrapped for treating RA in human and collagen-induced arthritis in animal models (rat, mouse, monkey, etc); major basic protein and its immunodominant peptide for multiple sclerosis in human and experimental
10 autoimmune encephalitis in animal models (rat, mouse, etc); GAD for IDDM in human and experimental diabetes mellitus in animal models (rat, mouse, etc); and S antigen for autoimmune uveitis in human and autoimmune uveitis in animal models (rat, mouse, etc).

The mammals to which the present invention can be applied may include, but
15 not limited to, rat, mouse, monkey, various experimental animal models, and human.

The biodegradable and biocompatible polymers which may be employed according to the present invention includes, but not limited to, poly(DL-lactide), polyglycolic acid, poly(DL-lactide-co-glycolide)('PLGA'), poly(epsilon-caprolactone) and the like. The PLGA is preferred for use in accordance with the
20 present invention since its safety in living body is well established. Polymeric materials for preparation of the particles are available commercially. These biodegradable polymers degrade through hydrolysis of polymer linkages to yield biocompatible products such as lactic acid and glycolic acid for PLGA, upon exposure to water.

25 The term of 'PLGA' is used herein to refer to the various copolymers of lactic and glycolic acids, which can be represented by following general formula:



PLGA 50:50 (x : y = 50 : 50)

The molecular weight of the polymers ranges from about 25,000 Daltons to about 120,000 Daltons. The ratio of lactide units to glycolide units ranges from 100:0 to 50:50. For example, PLGA having a ratio of lactide : glycolide = 85:15, which can be obtained from Birmingham Polymers, Incorporated, has an inherent viscosity of 0.58 dL/g and a molecular weight of approximately 90,900 daltons. It has been reported to have a biodegradation time up to approximately 10 months, depending on surface area, porosity and molecular weight. On the other hand, 50:50 PLGA polymer has a reported degradation time of 2 months.

The particles of biodegradable polymers (hereinafter, referred sometimes as simply 'particles') have a diameter ranging from one hundred nanometer to several thousand nanometers, preferably less than about 500nm, and more preferably about 200 to about 300nm. The particles may be prepared by conventional method, for example, by dispersing an organic solution of the polymer into an aqueous solution and then evaporating the solvent.

The particles entrapping an autoimmune antigen may be prepared by conventional water-in-oil-in water emulsion solvent evaporation methods. For example, the biologically active ingredients in a suitable aqueous solvent is emulsified with a solution of biodegradable polymers in an organic solvent such as methylene chloride to form an oil-in-water (o/w) emulsion. Then the o/w emulsion is emulsified with an aqueous solution of water-soluble polymer (e.g. polyvinyl alcohol) to give a w/o/w emulsion. Then the resulting w/o/w emulsion is evaporated

to remove the organic solvent. When immunodominant peptide fragments are used as an autoimmune antigen, they may advantageously be coupled in advance to a proper polymer such as PEG (MW more than 2,000) or polypeptides in order to moderate their release rate from the particles. PEG may be advantageously used for
5 this purpose.

The particles have preferably a size of less than 500nm, and more preferably between 200nm and 300nm. The loading of antigen varies between about 0.5% and about 10%. Particles with desired size were obtained by optimizing various formulation parameters such as volume and concentration of each solution used, a
10 kind of surfactant materials, and time period of energy input, energy sources such as sonicator, homogenizer or vortex used to form the water/oil/water emulsions.

The particles without or with an antigen entrapped therein may be administered orally to mammals such as human, cats, dogs, rats, mice, monkeys and the like for the purpose of treating autoimmune diseases.

15 The dose of the particles for oral administration may vary and be determined by those skilled in the art depending on the kind and severity of the diseases and condition of the subjects. For example, to treat RA, the dose may be within the range 0.1 - 1000mg of PLGA/kg of weight, and preferably 1 - 100 mg of PLGA/kg of weight, and more preferably 10 - 40mg of PLGA/kg of weight.

20 When the particle entrapping CII or its immunogenic peptide fragments is used, the dose of antigen may be within the range of 1 - 10000 μ g, preferably 10 - 1000 μ g, and more preferably 20 - 160 μ g.

The particles without or with an entrapped antigen may be administered orally and only single administration thereof can give a significant and satisfactory
25 suppression of autoimmune response in mammals.

Examples

The present invention will be described in more detail by way of various

Examples, which should not be construed to limit the scope of the present invention.

MATERIALS AND METHODS

Animal

DBA1 mice obtained from Jackson Laboratories (Bar Harbor, ME) were
5 maintained in groups of three to five in polycarbonate cage and fed standard mouse
chow and water adlibitum. The environment was specific pathogen-free for the mice
obtained from Jackson Laboratories. Neonatal mice were obtained by breeding mice
in inventor's facility. Mice were immunized at 8-12 weeks as described previously
(25, 27, 28).

10 Preparation of type II collagen

Intact bovine CII was extracted and purified from articular cartilage of calf as
described previously (39). Following steps were carried out; solubilization with
pepsin from cartilage slices after removal of proteoglycans by exposure to neutral 4
M guanidine HCl, repeated precipitation from 0.5 M acetic acid at 0.86 M NaCl, and
15 dialysis against 0.02 M Na_2HPO_4 ; removal of pepsin and proteoglycans by DEAE
chromatography; and removal of type I collagen by differential salt precipitation at
neutral pH. Purity was confirmed by SDS-PAGE. Lyophilized native bovine CII was
dissolved in 0.1N acetic acid at 1mg/ml, dialyzed against 50 mM Tris, 0.2M NaCl,
and then sterilized by filtering through a 0.2 μm micropore filter.

20 Preparation of PLGA entrapping CII

Entrapping of CII within PLGA was performed as described previously (40).

A solution of bovine CII (10 % w/v) in 0.5 M acetic acid (internal aqueous phase) was initially emulsified with a solution of PLGA (3 % w/v) in methylene chloride (oil phase), using a probe sonicator to form a water-in-oil (w/o) emulsion. The resulting emulsion was added to a 5% (w/v) PVA solution (external water phase) followed by
5 second emulsification, resulting in a water-in-oil-in water (w/o/w) emulsion. The w/o/w emulsion was stirred over a magnetic stir plate overnight at room temperature to evaporate methylene chloride. Upon evaporation the volatile organic solvent was removed, resulting in an aqueous suspension of particles. Particles with proper size were then recovered by ultracentrifugation. The particles were washed twice with
10 water and resuspended in water prior to lyophilization. The particles are sometimes referred to as 'PLGA-CII' for simplicity. Figure 1 is an electroscopic picture of the PLGA particles having a size of about 300nm.

Peptide synthesis and entrapment of peptide with PLGA.

Immunodominant peptide fragment of bovine CII (255-270) :
15 CGEBGIAGFKGEQGPK (SEQ. ID. NO. 4) was synthesized and then entrapped with PLGA by organic solvent evaporation methods (40). Synthetic peptide was conjugated with polyethylene glycol (PEG, MW5000), because this peptide was short and not soluble in methylene chloride which was an organic solvent used in making particle. Conjugation of peptide with PEG (methoxy-PEG-NH₂) was as follows. The
20 linker of SPDP (N-Succinimidyl 3-[2-pyridyldithio] propionate) was used in conjugation of peptide with PEG. 30mg of PEG was dissolved in 0.2ml of phosphate buffer (20mM, pH 7.5) and 5mg of SPDP in 0.2ml of DMSO. The two solutions were mixed and incubated at room temperature for 1 hour. After the reaction, SPDP-conjugated PEG was separated by gel filtration column chromatography eluted with
25 distilled water at the flow rate of 0.5 ml/min, followed by freeze-drying the separated fractions. The resulted PEG-SPDP was dissolved with peptide (10mg) in 0.5ml of

phosphate buffer (20mM, pH 7.5), and incubated at room temperature overnight. The PEG-conjugated peptide was applied to the same gel filtration chromatography eluted with distilled water at the same flow rate (0.5ml/min). The purified fractions were freeze-dried and stored at -20°C.

5 PLGA entrapping peptide was prepared as the same method as described for the preparation of PLGA-CII. The solution of PEG-peptide(2.5mg) and PLGA (50mg) in methylene chloride (1.5ml) was emulsified with a solution of 5% PVA, using a probe sonicator for 20 seconds. The emulsion was stirred over a magnetic stir plate for 5 hours at room temperature to evaporate the organic solvent. After the
10 evaporation, the suspension was centrifuged at $500 \times g$ for 5 min to remove the particles. The resulting particles were washed twice by ultracentrifuging and resuspending, and lyophilized. The particles are sometimes referred to as 'PLGA-CII(255-270)' for the simplicity.

15 Induction of CIA and clinical evaluation of arthritis

Mice were immunized with native CII at 8 to 12 weeks of age. CII dissolved in 0.1 N acetic acid (2mg/ml) was emulsified (1:1 ratio) with CFA (Complete Freund Adjuvant) at 4°C. Mice were received 0.1ml of the emulsion containing 100 μ g CII into base of tail as a primary immunization. Booster injection(50 μ g CII) was given
20 into footpad on day 14. Mice were observed two to three times per week for onset, duration, and severity of joint inflammation over a period of 12 weeks after primary immunization. Each limb was assessed on a 0- to 4-point scale by the following criteria: 0 = normal; 1 = mild inflammation of a single area (i.e., either the midfoot, ankle, or toes); 2 = moderately severe arthritis involving toes and ankle or midfoot;
25 3 = severe arthritis involving entire paw; and 4 = severe arthritis resulting in ankylosis and loss of joint movement. Since the left foot that was used for booster immunization was excluded from the evaluation, the possible maximum arthritis

score was 12. Mean arthritic index, incidence of arthritis (%), and percent arthritic limbs were used for comparison and calculated as follows:

Mean arthritis index = Sum of the arthritic score / Total number of mice

Incidence of arthritis (%) =

$$5 \quad \frac{\text{Number of mice with arthritic score} > 2 \text{ in any limb}}{\text{Total number of mice}} \times 100$$

Percent arthritic limbs (%) =

$$10 \quad \frac{\text{Number of limbs with arthritic score} > 2}{\text{Total number of limbs}} \times 100$$

Tolerance induction

Mice were fed 8 times with 5 μ g CII on days -17, -15, -13, -11, -9, -7, -5, -3 relative to the primary immunization with CII in CFA on day 0. Control mice were
 15 fed 8 times with 0.1 N acetic acid. PLGA, PLGA-CII 40 μ g (cumulative dose of CII in mice repetitively fed with CII), or PLGA-CII(255-270) 4 μ g were fed only once on day -17.

Assessment of T cell proliferation

Draining or mesenteric lymph node, and spleen were removed from animal at
 20 14 days after immunization and dissociated and washed in RPMI 1640. Lymph nodes and spleen were individually minced into single cell suspensions in RPMI 1640 and washed three times. Cells (5 X 10⁵/well) were cultured in 96-well microtiter plates

(Nunc, Roskilde, Denmark) with or without 100 $\mu\text{g/ml}$ of CII in 0.3 ml of Click's medium supplemented with 0.5% mouse serum at 37°C, 5% humidified CO₂ for 4 days. Eighteen hours before the termination of the cultures, 1 μCi [³H] thymidine was added to each well. Cells were harvested onto glass fiber filters and counted on a
5 Matrix 96 direct ionization β -counter (Packard Instrument Co, Meridan, CT). The results are presented as stimulation indices (SI), calculated as the ratio of cpm in the presence of antigens / cpm without antigens.

Assay for IgG antibodies to bovine native type II collagen

Sera were collected on day 28 after primary immunization and stored at -20°C
10 until the assay. The levels of IgG anti-CII in sera were determined by enzyme-linked immunosorbent assays kit (Chondrex, Redmond, WA). The optical density of standard serum which was serially diluted 2-fold was expressed as 100, 50, 25, 12.5, 6.25, 3.125 arbitrary units (a.u.), respectively, according to the manufacture's instructions. The relationship of the optical density measured in standard serum
15 diluted serially and arbitrary unit showed a good linear correlation in all determinations ($r > 0.98$, data not shown). The concentrations of IgG anti-CII in the sera diluted 1: 4000 are presented as relative values (a.u.) compared to the optical density of the standard serum which was diluted serially.

Immunohistochemical staining of CII in Peyer's patch

20 To determine whether CII entrapped within PLGA is still present in the intestine for a long period, immunohistochemical staining of CII was performed in Peyer's patches. Briefly, Peyer's patches were obtained from mice administered orally PLGA entrapping CII on days 14 and 35 after feeding. Peyer's patches from mice fed with repetitive CII or acetic acid was used for control tissue. After fixing with

periodate-lysine paraformaldehyde solution at 4°C overnight, tissues were dehydrated with alcohol. After washing, wax (polyethylene glycol 400 distearate) embedding and microsection (5 μ m) of tissue were done. To remove peroxidase activity within tissue, methanolic H₂O₂ was added and then tissues were blocked with normal sera for 1 hour. After tissue were incubated overnight with goat monoclonal antibodies to bovine CII, generous gifts from Dr. Andrew H Kang, DAG (peroxidase conjugated F(ab')₂, Donkey anti-goat IgG, Jackson Immunoresearch Laboratories) was added to tissue. Biotinylated antibody was then added to tissues and color reaction was detected with diaminobenzidine (DAB) on microscopy.

10 ***In vitro* release of entrapped antigen from PLGA**

The *in vitro* release of CII from PLGA particles was evaluated for 4 weeks under physiologic conditions at 37°C. FITC-labeled collagen was used in *in vitro* release test to increase sensitivity. After labeling collagen with FITC, the particles were prepared as described above. Then, the particles were dispersed in phosphate buffer (PH 7.4, 0.1M) and maintained at 37°C with mild stirring. Keeping the sample in this condition, an aliquot of the sample was taken and its fluorescence was measured by spectrofluorometer periodically.

Characterization of particles by electron microscopy

Scanning electron microscopy (SEM) was performed to determine the surface topography of the particles. Particles were gold coated using a sputter gold coater (Denton Vacuum Inc, Cherry Hill, NJ) at 40 miliampere current and 50 millitorr pressure for 200 seconds to the thickness of 300 Å. Samples of gold coated particles were cooled over dry ice prior to SEM observations to avoid their melting under magnification due to electron beam exposure (Hitachi S570, Chery Hill, NJ). To

characterize PLGA particles *in vivo* and to determine whether PLGA particles are still present in the intestine for a long period, a ultra-thin frozen section of Peyer's patches was obtained on days 14 and 35 after feeding of PLGA-CII and then the presence of PLGA particles was investigated on electron microscopy.

5 Statistics

Comparisons of numerical data between groups were performed by the student T-test and ANOVA and for categorical data by a chi-square test or Fisher's exact probability test. P values less than 0.05 were considered significant.

RESULTS

10 1. Characterization of PLGA particles

Particles with desired size were obtained by optimizing various formulation parameters and energy source input used to form the water/oil/water emulsions. As can seen from the SEM analysis, nanoparticles were spherical with smooth uniform surfaces with more than 80% particles in the desired size range. Discrete spherical
15 particles had a mean diameter of 299.7 ± 4.9 nm (Figure 1). To find out collagen loading of particles, weighed particles were dissolved in 0.4 N NaOH, 10 % SDS (w/v) solution. And then, the solution was assayed for collagen by Lowry method. 1.2 % of total weight was composed of collagen. Encapsulation efficiency was approximately 6.5%.

20 This study demonstrated that PLGA particles produced *in vitro* an initial burst release of 10 to 20% of encapsulated CII within two days. The subsequent release of CII up to 20 days was at a slower releasing rate during which 10% to 20% of CII was

released. The slow release phase was followed by a second burst release from day 15 to 30 possibly due to hydrophobic erosion of the polymer matrix (Figure 2).

2. Establishment of collagen induced arthritis

5 Figure 3(a) and 3(b) shows the incidence and severity of collagen-induced arthritis with the lapse of time in an animal model, respectively.

As shown in Figure 4(b) and 4(c), in mice (n=9) fed acetic acid and injected with CII and CFA, CIA developed from 3 weeks. The severity and incidence of arthritis peaked at 5 weeks, reaching 5.1 of mean arthritic index (maximum 12) and
10 100% of incidence, respectively and were decreased over time thereafter, which is consistent with previous reports (25, 27, 28).

3. Tolerance induction with PLGA entrapping CII

To test the ability of single administration of PLGA-CII to suppress CIA, the mean arthritis index, incidence, and number of arthritic limbs were compared
15 between mice (n=8) fed with PLGA-CII once and those fed with eight times of CII (n=8) or acetic acid (n=8), at five weeks after primary immunization. As shown in Figure 5, mice fed with PLGA-CII and mice fed with CII had significant lower levels of the mean arthritis index (PLGA-CII 0.9 ± 0.3 , CII 2.8 ± 0.9 , acetic acid 4.5 ± 1.1 , $p < 0.001$), incidence (PLGA-CII 0%, CII 50%, acetic acid 100%, $p < 0.001$), and
20 number of arthritic limbs (PLGA-CII 0/24 [0%], CII 5/24 [20.8%], acetic acid 14/24 [58.3%], $p < 0.001$) compared to those fed with acetic acid. Comparison of clinical parameters between PLGA-CII and CII fed mice showed that mice fed with PLGA-CII had significant lower levels of the mean arthritis index ($p < 0.001$), incidence ($p = 0.02$), and number of arthritic limbs ($p = 0.008$) compared to those fed
25 with CII. These observation demonstrated that the single administration of PLGA-CII

successfully suppressed the incidence of and relieved the severity of arthritis, and even more effective to induce tolerance compared to repetitive administration with same cumulative dose of CII. Figure 5 showed a remarkable decrease of paw swelling in tolerized mice fed CII or PLGA-CII compared to acetic acid fed mice.

5 4. Tolerance induction using PLGA entrapping CII (255-274).

The mean arthritis index, incidence, and number of arthritic limbs were lower in mice (n=4) fed with PLGA-CII (255-274) compared to mice (n=4) fed with acetic acid, at five weeks after primary immunization. Mean arthritis index; 3.5(0.6 versus 1.0(0.8, p=0.002, incidence; 25% versus 100%, number of arthritic limbs 1/12 [8.3%]
10 versus 4/12 [33.3%] (Figure 6). These data strongly suggest that PLGA-CII (255-270) may be useful to treat RA. In addition, a single administration of PLGA entrapping synthetic peptides could be applicable to treat other autoimmune diseases such as multiple sclerosis, autoimmune uveitis, and insulin dependent diabetes mellitus (IDDM) in which repetitive oral administration of synthetic
15 immunodominant peptides is known to be effective to suppress disease severity. In this context, representative synthetic peptides containing immunodominant portions of autoantigen, which can be entrapped in PLGA, are listed in the above.

5. Assessment of the ability of PLGA to induce tolerance

In addition to the slow release property of entrapped protein, several kinds of
20 particulate antigen are known to have a potential to modulate immunogenicity by itself. To assess the ability of PLGA itself to induce tolerance, the inventors conducted a series of CIA induction in mice fed with PLGA. As a result, mice fed once with PLGA (n=8) had significant lower levels of mean arthritis index and percent arthritic limbs compared to mice fed with acetic acid (n=7) when assessed at

5 weeks after primary immunization (mean arthritic index; 1.8 ± 0.8 versus 3.9 ± 1.9 , $p=0.019$, percent arthritis limb; 10/21 [12.9%] versus 3/24 [42.9%], $p=0.01$) (Figure 7(a)).

The incidence of arthritis also tended to be lower in mice fed with PLGA than those fed with acetic acid ($p=NS$). Comparison of clinical parameters at 5 weeks between PLGA and PLGA-CII administered mice showed that the incidence of arthritis was significantly lower in mice fed with PLGA-CII than PLGA alone (0% versus 50%, $p=0.03$). Mean arthritis index and percent arthritic limb tended to be lower in PLGA-CII fed mice, but they did not reach statistical significance (Figure 7(b)). These data demonstrated that PLGA alone could suppress CIA, but its potency was more enhanced by CII entrapping. These observations are strong evidences that tolerogenicity by PLGA-CII is achieved by the mechanism of immunosuppressive effect of PLGA itself (tolerance inducing effect) as well as repetitive stimulation of intestinal immune cells by PLGA-CII as a carrier system (tolerance enhancing effect).

15 6. Effect of PLGA-CII on autoimmune response to CII

Circulating IgG antibodies to CII were significantly lower in CII-fed ($n=9$) and PLGA-CII-fed mice ($n=9$) compared to acetic acid-fed mice ($n=9$) (PLGA-CII; 6.4 ± 7.7 , CII; 15.2 ± 18.9 , acetic acid; 1.8 ± 0.8 , $p<0.01$). PLGA-fed mice tended to have lower levels of IgG antibodies to CII compared to CII-fed mice ($p=NS$). Assay for T cell proliferative responses to CII in draining or mesenteric lymph node and spleen also showed that mice fed with PLGA-CII, PLGA and CII had lower levels of T cell proliferative responses to CII (Figure 8(a) and 8(b)). These observations clearly showed that PLGA-CII or PLGA itself could suppress both humoral and cellular autoimmune responses systemically when administered orally, which constructs an important mechanism of PLGA to induce tolerance since both T cells responding to CII and IgG antibodies to CII, are known to play a critical role in

arthritis induction of susceptible animals.

7. Identification of PLGA particles in Peyer's patches

To characterize PLGA particles *in vivo* and to determine whether PLGA
5 particles are still present in the intestine for a long period, the presence of PLGA
particles was investigated in Peyer's patches on days 14 and 35 after feeding of
PLGA, which is the time that any soluble antigen can not be detected in the intestine,
by electron microscopy. As shown in Figure 9(b), PLGA particles having a size of
about 300 nm were found in dendritic cells of Peyer's patches in an aggregated
10 manner. They were located on the cytoplasm in an intact form as well as on
lysosome granules in a degraded form. Surprisingly, dendritic cells phagocytosing
PLGA particles revealed an increased amount of lysosome granules, indicating
cellular activation.

However, these findings were not detected in Peyer's patches from mice fed
15 CII or acetic acid, repetitively (Figure 9(a)). Recently, it is reported that hyperplasia
or activation of dendritic cells plays a pivotal role in tolerance induction, in contrast
with the generally accepted view of dendritic cells as immunostimulatory antigen
presenting cells. Our data clearly showed that, like results from *in vitro* release test,
PLGA particles were present in dendritic cells of Peyer's patches with a slow
20 degradation, at least up to 35 days and could activate dendritic cells, which may
explain how PLGA particles can suppress the systemic autoimmune response to CII
as well as the incidence and severity of arthritis. This may be one of the possible
mechanism that PLGA particles contribute to tolerance induction (tolerance induction
effect).

25 8. Persistence of CII in Peyer's patches from mice single fed PLGA-CII

On CII specific immunohistochemical staining of Peyer's patches, we found that CII was densely stained around dendritic cells from PLGA-CII fed mice on days 14 and 35, which is the time that any soluble antigen can not be normally detected in the intestine, which is consistent with the findings in *in vitro* release test (Result 1, 5 Figure 3). However, these findings were not noted in mice fed with CII or acetic acid, repetitively (Figure 10). These findings demonstrated that CII was protected from acids and enzymatically hostile environments and released slowly from PLGA. This is also persuasive evidence that PLGA-CII contributes to tolerance induction in a manner of chronic antigenic stimulation of intestinal immune cells, driven by 10 long-lasting CII.

Although preferred embodiments of the present invention have been described in detail herein above, it should be clearly understood that many variations and/or modifications of the basic inventive concepts herein taught which may appear to those skilled in the art will still fall within the spirit and scope of the present 15 invention as defined in the appended claims.

References

1. Weiner HL, Mackin GA, Matsui M, et al: Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. *Science* 259:1321-1324, 1993.
2. Trentham DE, Dynesius-Trentham RA, Orav EJ, et al: Effects of oral administration
5 of type II collagen on rheumatoid arthritis. *Science* 261:1727-1730, 1993.
3. Zhang ZJ, Davidson L, Eisenbarth G, et al: Suppression of diabetes in non-obese diabetic mice by oral administration of porcine insulin. *Proc Natl Acad Sci USA* 88:10252-10256, 1991.
4. Nussenblatt RB, Caspi RR, Mahdi R, et al: Inhibition of S-antigen induced
10 experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. *J Immunol* 144:1689-1695, 1990.
5. Sun JB, Holmgren J, Czerkinsky C : Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. *Proc Natl Acad Sci USA* 91:10795-10799, 1994.
- 15 6. Melamed D, Friedman A: *In vivo* tolerization of Th1 lymphocytes following a single feeding with ovalbumin: anergy in the absence of suppression. *Eur J Immunol* 24:1974-1981, 1994.
7. Melamed D, Fishman-Lovell J, Uni Z, et al: Peripheral tolerance of Th2 lymphocytes induced by continuous feeding of ovalbumin. *Int Immunol* 8:717-724, 1996.
- 20 8. Stokes CR, Swarbrick ET, Soothill JF: Genetic differences in immune exclusion and partial tolerance to ingested antigens. *Clin Exp Immunol* 52:678-684, 1983.
9. Moreau MC, Coste M, Gaboriau V, et al: Oral tolerance to ovalbumin in mice: effect of some parameters on the induction and persistence of the suppression of systemic IgE and IgG antibody responses. *Adv Exp Med Biol* 371:1229-1234, 1995.
- 25 10. Peng HJ, Chang ZN, Han SH, et al: Chemical denaturation of ovalbumin abrogates the induction of oral tolerance of specific IgG antibody and DTH responses in mice. *Scand J Immunol* 42:297-304, 1995.
11. Peng HJ, Turner MW, Strobel S: The generation of a 'tolerogen' after the ingestion of ovalbumin is time-dependent and unrelated to serum levels of immunoreactive antigen. *Clin*

- Exp Immunol 81:510-515, 1990.
12. Hanson LA, Telemo E, Wiedermann U, et al : Sensitization and development of tolerance via the gut. *Pediatr Allergy Immunol* 4:16-20, 1993.
13. Couvreur P, Puisieux F: Nano- and microparticles for the delivery of polypeptides and
5 proteins: *Adv. Drug Del. Rev* 10:141, 1993.
14. Lavelle EC, Sharif S, Thomas NW, et al: The importance of gastrointestinal uptake of particles in the design of oral delivery systems. *Adv. Drug Del. Rev* 18:5, 1995.
15. Andrianov AK, Payne LG: Polymeric carriers for oral uptake of microparticulates: *Adv. Drug Del. Rev* 34:155, 1998.
- 10 16. Florence AT: The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual: *Pharm. Res* 14:259, 1997.
17. Jani P, Halbert GW, Langridge J, et al: Particle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency: *J. Pharm. Pharmacol* 42: 821, 1990.
18. Jani P, Florence AT, McCarthy DE: Further Histological evidence of the
15 gastrointestinal absorption of polystyrene nanospheres in the rat: *Int. J. Pharm* 84:245, 1992.
19. Jepson MA, Clark MA, Foster N et al: Targeting to intestinal M cells. *J. Anat.* 189: 507-516, 1996.
20. Moldoveanu Z, Novak M, Huang W-Q et al: Oral immunization with influenza in biodegradable microspheres. *J. Infect. Dis* 167: 84-90, 1993.
- 20 21. Smith MW, Thomas NW, Kenkins PG, et al: Selective transport of microparticles across Peyer's patch follicle-associated M cells from mice and rats. *Exp Physiol.* 80: 735-743, 1995.
22. Krey A, Giannasca KT, Weltzein R et al. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: Implications for
25 microbial attachment and oral vaccine targeting. *J. Exp. Med* 184:1045-1059, 1996.
23. Teitelbaum D, Arnon R, Sela M: Immunomodulation of experimental autoimmune encephalitis by oral administration of copolymer 1. *Proc Natl Acad Sci USA* 96:3842-3847, 1999.
24. Fridkis-Hareli M, Rosnoleic E, Fugger L, et al: Synthetic amino acid copolymers that
30 bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones.

25. Ito HO, So T, Ueda T, et al: Prevention of collagen induced arthritis (CIA) by treatment with polyethylene glycol-conjugated type II collagen; distinct tolerogenic property of the conjugated collagen from the native one. *Clin Exp Immunol* 108:213-219, 1997.
26. Heritage PL, Loomes LM, Jianxiong J, et al. Novel polymer-grafted starch
5 microparticles for mucosal delivery of vaccines. *Immunology*. 88:162-168, 1996.
27. Trentham DE, Townes AS, Kang AH: Autoimmunity to type II collagen: An experimental model of arthritis. *J Exp Med* 146:857-868, 1977.
28. Courtenay JS, Dallman MJ, et al: Immunisation against heterologous type II collagen induces arthritis in mice. *Nature* 283:666-668, 1980.
- 10 29. Trentham DE, Dynesius RA, et al: Cellular sensitivity to collagen in rheumatoid arthritis. *N Eng J Med* ;299:327-332, 1978.
30. Rudolphi U, Rzepka R, Batsford S, et al: The B cell repertoire of patients with rheumatoid arthritis. Increased frequencies of IgG+ and IgA+ B cells specific for mycobacterial heat-shock protein 60 or human type II collagen in synovial fluid and tissue.
15 *Arthritis Rheum* 40:1409-1419, 1997.
31. Tarkowski A, Klareskog L, Carlsten H, et al: Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis. *Arthritis Rheum* 32:1087-1092, 1989.
32. Barnett ML, Kremer JM, Clair EW, et al: Treatment of rheumatoid arthritis with oral
20 type II collagen : Results of a multicenter, double-blind, placebo-controlled trial. *Arthritis Rheum* 41:290-297, 1998.
33. Sieper J, Kary S, Sorensen H, et al: Oral type II collagen treatment in early rheumatoid arthritis : a double-blind, placebo-controlled, randomized trial. *Arthritis Rheum* 39:41-51, 1996.
- 25 34. Khare SD, Krcó CJ, Griffiths MM, et al: Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. *J Immunol* 155:3653-3659, 1995.
35. Krcó CJ, Pawelski J, Harders J, et al: Characterization of the antigenic structure of human type II collagen. *J Immunol*:156:2761-2768, 1996.
- 30 36. Yu M, Johnson JM, Tuohy VK: A predictable sequential determinant spreading

cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide specific therapy after onset of clinical disease. *J Exp Med* 183:1777-1788, 1996.

37. Tuohy VK, Yu M, L, et al: Spontaneous regression of primary autoreactivity during
5 chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis.
J Exp Med 189:1033-42, 1999.

38. Vrabec TR, Gregerson DS, Dua HS, et al: Inhibition of experimental autoimmune uveoretinitis by oral administration of S-antigen and synthetic peptides. *Autoimmunity* 12:175-84, 1992.

- 10 39. Stuart JM, Cremer MA, Kang AH, et al: Collagen induced arthritis in rats: evaluation
of early immunologic events. *Arthritis Rheum* 22:1344, 1978.

40. Desai MP, Labhasetwar V, Amidon GL, et al: Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size. *Pharm. Res* 13: 1838, 1996.

41. Kakimoto K, Katsuki M, Hirofujii T, et al: Isolation of T cell line capable of
15 protecting mice against collagen induced arthritis in mice. *J Immunol* 140:78-83, 1988.

42. Chen SL, Whiteley PJ, Freed DC, et al: Responses of NOD congenic mice to a glutamic acid decarboxylase-derived peptide. *J Autoimmunity*. 7:635-41, 1994.

CLAIMS

1. A method for treating autoimmune diseases, which comprises administering orally to a mammal suffering from autoimmune diseases particles of biodegradable polymers in an amount of effective to induce tolerance against autoimmune response.
- 5 2. The method according to Claim 1, wherein said biodegradable polymers are poly(DL-lactide-co-glycolide), polylactides or polyglycolides.
3. The method according to Claim 1, wherein said autoimmune diseases are one of Th1-mediated or T cell-mediated autoimmune diseases selected from the group consisting of rheumatoid arthritis, insulin dependnent diabetes mellitus,
10 uveitis, multiple sclerosis, autoimmune thyroiditis, autoimmune hepatitis, interstitial pneumonitis and glomerulonephritis, and their corresponding diseases in animal models.
4. The method according to Claim 3, wherein said autoimmune disease is rheumatoid arthritis.
- 15 5. The method according to any one of Claim 1 to Claim 4, wherein said mammal is human, rats, mice and monkeys.
6. The method according to any one of Claim 1 to Claim 4, wherein a single dose of said particles is administered to induce tolerance against autoimmune response.
- 20 7. The method according to any one of Claim 1 to Claim 4, wherein said particles have a size of less than about 500nm.

8. A method for treating autoimmune diseases, which comprises administering orally to a mammal suffering from autoimmune diseases particles of biodegradable polymers entrapping an autoimmune antigen, said particles being administered in an amount of effective to induce tolerance against autoimmune
5 response.

9. The method according to Claim 8, wherein said biodegradable polymers are poly(DL-lactide-co-glycolide), polylactides or polyglycolides.

10. The method according to Claim 8, wherein said autoimmune diseases are one of selected from the group consisting of rheumatoid arthritis, collagen induced
10 arthritis, multiple sclerosis, experimental autoimmune encephalomyelitis, insulin-dependent diabetes mellitus, experimental diabetes mellitus and uveitis.

11. The method according to Claim 10, wherein said autoimmune disease is rheumatoid arthritis.

12. The method according to Claim 8, wherein said antigen is type II collagen,
15 S antigen, major basic protein, glutamic acid decarboxylase, or immunodominant peptide fragments thereof.

13. The method according to any one of Claim 8 to Claim 12, wherein said mammal is human, rats, mice and monkeys.

14. The method according to any one of Claim 8 to Claim 12, wherein a single
20 dose of said particles is administered to induce tolerance against autoimmune response.


15. The method according to any one of Claim 8 to Claim 12, wherein said particles have a size of less than about 500nm.

16. A composition for inducing tolerance for autoimmune diseases, which comprises as an active ingredient particles of biodegradable polymers in an amount
5 of effective to induce tolerance against autoimmune response.

17 A composition for inducing tolerance for autoimmune diseases, which comprises as an active ingredient particles of biodegradable polymers entrapping an autoimmune antigen in an amount of effective to induce tolerance against autoimmune response.


1 / 12

FIG. 1



2 / 12


FIG. 2




3 / 12

FIG. 3

(a)




(b)




4 / 12

FIG. 4

(a)




(b)



5 / 12


FIG. 4

(c)



6 / 12


FIG. 5




7 / 12

FIG. 6

(a)




(b)




8 / 12

FIG. 7

(a)




(b)




9 / 12

FIG. 8

(a)



(b)



10/ 12

FIG. 9


(a)



11/ 12


FIG. 9

(b)



12/ 12

FIG. 10



SEQUENCE LISTING

<110> KIM, Ho-Youn
Park, Jong-Sang

<120> Immunological Tolerance-Induction Agent

<130> pct99081

<140> PCT/KR99/00000

<141> 1999-08-18

<160> 11

<170> PatentIn Ver. 2.0

<210> 1

<211> 20

<212> PRT

<213> Homo sapiens

<400> 1

Ala	Arg	Gly	Phe	Pro	Gly	Thr	Pro	Gly	Pro	Gly	Gly	Val	Lys	Gly	His
1				5					10					15	

Arg	Gly	Tyr	Pro
			20

<210> 2

<211> 20

<212> PRT

<213> Homo sapiens

<400> 2

Thr	Gly	Gly	Lys	Pro	Gly	Ile	Ala	Gly	Phe	Lys	Gly	Glu	Gln	Gly	Pro
1				5					10					15	

Lys	Gly	Glu	Pro
			20

<210> 3

<211> 20

<212> PRT

<213> Homo sapiens

<400> 3

Pro Gly Glu Arg Gly Leu Lys Gly His Arg Gly Phe Thr Gly Leu Gln
1 5 10 15

Gly Leu Pro Gly
20

<210> 4
<211> 16
<212> PRT
<213> Bovine

<400> 4
Cys Gly Glu Asx Gly Ile Ala Gly Phe Lys Gly Glu Gln Gly Pro Lys
1 5 10 15

<210> 5
<211> 13
<212> PRT
<213> Homo sapiens

<400> 5
His Ser Leu Gly Lys Trp Leu Gly His Pro Asp Lys Phe
1 5 10

<210> 6
<211> 14
<212> PRT
<213> Homo sapiens

<400> 6
Asn Thr Trp Thr Thr Cys Gln Ser Ile Ala Phe Pro Ser Lys
1 5 10

<210> 7
<211> 16
<212> PRT
<213> Homo sapiens

<400> 7
Ile Ala Ala Thr Tyr Asn Phe Ala Val Leu Lys Leu Met Gly Arg Gly
1 5 10 15

<210> 8

<211> 13
<212> PRT
<213> Homo sapiens

<400> 8
Val His Phe Phe Lys Asn Ile Val Thr Pro Arg Thr Pro
1 5 10

<210> 9
<211> 15
<212> PRT
<213> Homo sapiens

<400> 9
Asp Glu Gly Gly Tyr Thr Cys Phe Phe Arg Asp His Ser Tyr Gln
1 5 10 15

<210> 10
<211> 20
<212> PRT
<213> Homo sapiens

<400> 10
Leu Gly Glu Leu Thr Ser Ser Glu Val Ala Thr Glu Val Pro Phe Arg
1 5 10 15

Leu Met His Pro
20

<210> 11
<211> 20
<212> PRT
<213> Homo sapiens

<400> 11
Ser Arg Leu Ser Lys Val Ala Pro Val Ile Lys Ala Arg Met Met Glu
1 5 10 15

Thr Gly Thr Thr
20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 99/00460

CLASSIFICATION OF SUBJECT MATTER

IPC⁷: A 61 K 39/39, 38/02; C 07 K 14/435, 14/78, 17/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: A 61 K; C 07 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, registry, cas

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/37315 A1 (BAI) 29 July 1999 (29.07.99) abstract; page 20, lines 12-22; claims.	8-15,17
X	WO 99/09956 A1 (CORIXA CORPORATION) 4 March 1999 (04.03.99) abstract; claims.	1-7
X	WO 99/02186 A2 (LYFJA ROUN HF ICELANDIC BIO PHARM GROUP) 21 January 1999 (21.01.99) abstract; claims.	1,3-7,17
A	US 5691448 A (BAEKESKOV et al.) 25 November 1997 (25.11.97) abstract; claims.	1-17

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&“ document member of the same patent family

Date of the actual completion of the international search

14 April 2000 (14.04.2000)

Date of mailing of the international search report

31 July 2000 (31.07.2000)

Name and mailing address of the ISA/AT

Austrian Patent Office
Kohlmarkt 8-10; A-1014 Vienna

Facsimile No. 1/53424/535

Authorized officer

Krenn

Telephone No. 1/53424/435

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 99/00460

Box I Observations where certain claims were found unsearchable (Continuation of item I of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: please see remark
because they relate to subject matter not required to be searched by this Authority, namely:

REMARK: Although claims 1-15 are directed to a therapeutic method of treatment of (diagnostic method practised on) the human/ animal body, the search has been carried out and based on the alleged effects of the compound/ composition (see Rule 39iv).
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 99/00460

Patent document cited in search report				Publication date		Patent family member(s)	Publication date
WO	A1	9937315		29-07-1999		AU A1 25667/99	09-08-1999
WO	A1	9909956		04-03-1999		AU A1 91256/98	16-03-1999
						EP A1 1009386	21-06-2000
WO	A2	9902186		21-01-1999		AU A1 84598/98	08-02-1999
WO	A3	9902186		01-04-1999		EP A2 1003551	31-05-2000
US	A	5691448		25-11-1997		EP A1 701569	20-03-1996
						EP A4 701569	20-08-1997
						JP T2 8504406	14-05-1996
						WO A1 9412529	09-06-1994
						US A 5674692	07-10-1997
						US A 5849506	15-12-1998
						US A 5998584	07-12-1999
						US A 5512447	30-04-1996
						EP A1 693183	24-01-1996
						EP A4 693183	29-04-1998
						JP T2 8509289	01-10-1996
						WO A1 9424564	27-10-1994
						AU A1 87219/91	30-03-1992
						EP A1 547164	23-06-1993
						EP A4 547164	26-01-1994
						JP T2 6502916	31-03-1994
						JP B2 2727377	11-03-1998
						WO A1 9204632	19-03-1992